TITLE:
Radiotherapy of Esophageal Carcinomas at the Dantec University Hospital of Dakar from 2010 to 2015
AUTHORS:
Papa Macoumba Gaye, Mouhamadou Bachir Ba, Dabbo Dieng, Mamadou Moustapha Dieng, Ahmadou Dem
KEYWORDS:
Radiotherapy, Esophageal, Sénégal
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.5,
May
19,
2020
ABSTRACT: We performed a descriptive
retrospective study of radiotherapy of esophageal carcinomas at the Dantec
University Hospital in Dakar from 2010 to 2015. The aim was to describe the
type of patient, and to evaluate the indication and the results of the irradiation. We
consulted 117 cases and selected 26 cases. The average age of patients is 46.1 years (Extremes 17 - 83 years and
peaks 30-39 and 50 - 59 years). The sex ratio
is 1.67. Smoking was reported in 38.4% of cases and alcoholism in 15.3%.
Dysphagia is the predominant sign (100% of patients). The general condition is
classified WHO 1 for 42.3% of cases. The tumor was localized in 61.5% in the
lower third and is stenosing in 84.6% of our patients. Squamous cell carcinoma
is the most common type (88.5% of cases). The size of the tumor, specified in
50% of cases, varies from 2.6 to 11.2 cm. Computed tomography is performed in
more than 50% of cases. Endoscopic ultrasonography is not performed and surgical
exploration has contributed to the staging of 7.7% of irradiated patients. The
tumor is localized in 47.8% of cases; at an advanced stage in 52% and is metastatic
in 4.3%. We note a transhiatal excision and a gastrostomy in 15% and 69% of the
cases and no surgery of excision in healthy margin. Chemotherapy or neoadjuvant
radiotherapy is not performed. The radiotherapy was: exclusive (11%), adjuvant after
surgery in margin R2 (15%), palliative in 3 × 5 Gy per 3 week (4%) and concomitant with chemotherapy
cisplatyl 5FU (70%). The spread ranges from 2 to 6 weeks. The partial and complete
response rate is 38.4% and 11.5%. The stabilization is 30.7% and the
progression is 19.4%. Grade I-2 toxicity was noted in 46.1% (asthenia, radiodermatitis,
cough) and grade 3 radiodermite in 4%. The average follow-up time is 198.19
days with extremes of 2 days and 32 months.